Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 133-143 , April 2000

Intraperitoneal chemotherapy in ovarian cancer

References 

  1. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993;71:517–523
  2. Cannistra SA. Cancer of the ovary. N Engl J Med. 1993;329:1550–1559
  3. McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med. 1996;335:1950–1955
  4. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Sem Oncol. 1998;25:340–348
  5. Bergman F. Carcinoma of the ovary. A clinopathological study of 86 autopsied cases with special reference to the mode of spread. Acta Obstet Gynecol Scand. 1966;45:211–231
  6. Dedrick R, Myers C, Bungay P. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11
  7. Babb AL, Johasen PJ, Strand MJ. Biderectional permeability of the human – peritoneum to middle molecules. Proc Eur Dial Transplant Assoc. 1993;10:247–261
  8. Maher JF. Peritoneal transport rates: Mechanisms, limitations and methods for augmentation. Kidney Int. 1980;18:117–120
  9. Litterst CI, Torres IJ, Sikic BI. Absorption of antineoplastic drugs following large volume IP administration to rats. Cancer Treat Rep. 1980;66:147–155
  10. Ozols RF, Locker GY, Doroshow JH. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian carcinoma. Cancer Res. 1979;39:3209–3214
  11. Los G, Verdegaal E, Mutsaers P. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–165
  12. Markman M, Reichman B, Hakes T. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol. 1993;50:100–104
  13. Barakat R, Fennelly D, Pizutto F. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: Impact of retroperitoneal nodal disease. Eur J Gynaecol Oncol. 1997;18:161–163
  14. Rosenhein N, Blake D, McIntyre P. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol. 1978;6:106–110
  15. Levenback C, Curtin J, Johnston D. Image analysis of the distribution of intraperitoneally administered fluids in patients with ovarian cancer. Eur J Gynaecol Oncol. 1994;15:345–351
  16. Myers C. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol. 1984;11:274–284
  17. Myers C. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol. 1984;11:274–284
  18. Jenkins J, Sugarbaker PH, Gianola FJ. Technical considerations in the use of of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet. 1982;154:858–864
  19. Kaplan , Markman M, Lucas WE. Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med. 1985;78:49–53
  20. Almadrones L, Yerys C. Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system. Oncol Nurs Forum. 1990;17:75–80
  21. Malmstrom H, Carstensen J, Simonsen E. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer patients. Gynecol Oncol. 1994;54:27–34
  22. Naumann RW, Alvarez RD, Partridge EE. The Groshong catheter as an intraperitoneal access device in the treatment of ovarian cancer patients. Gynecol Oncol. 1993;50:291–293
  23. Howell S, Pfeifle C, Wung W. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–851
  24. Pretorius RG, Hacker NF, Berek JS. Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983;67:1085–1092
  25. Casper ES, Kelsen DP, Alcock NW. IP cisplatin in patients with malignant ascites. Pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep. 1983;67:235–238
  26. Malmstrom H, Larsson D, Simonsen E. Phase I study of intraperitoneal carboplatin as adjuvant therapy in early ovarian cancer. Gynecol Oncol. 1990;39:289–294
  27. Elferink F, Van der Vijgh WJ, Klein I. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol. 1988;21:57–60
  28. Guastella JP, Lhomme C, Kerbrat P. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French federation Nationale des Centre de Lutte Contre le Cancer. Ann Oncol. 1994;5:127–132
  29. Speyer JL, Sorich J. Intraperitoneal carboplatin: rationale and experience. Semin Oncol. 1992;19:107–113
  30. Markman M, Rowinsky E, Hakes T. Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group Study. J Clin Oncol. 1992;9:1485–1491
  31. Francis P, Rowinsky E, Schneider J. Phase I feasibility and pharmacological study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group Pilot Study. J Clin Oncol. 1995;13:2961–2967
  32. Willemse PHB, Hofstra LS, Beijnen JH. Primary intraperitoneal paclitaxel combined with CBDCA/Cytoxan (CC) in advanced ovarian cancer: a phase II study. Proc Am Soc Clin Oncol. 1997;16:#1360
  33. Ten Bokkel Huinink W, Gore M, Carmichael J. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–2193
  34. Bookman MA, Malmstrom H, Bolis G. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345–3352
  35. Plaxe SC, Christen RD, O’Quigley J. Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs. 1998;16:147–153
  36. Hofstra LS, De Vries EGE, Van der Zee AGJ. Phase I/II and pharmacokinetic study of intraperitoneal topotecan. Proc Am Soc Clin Oncol. 1998;17:#935
  37. O’Dwyer PJ, LaCreta FP, Daugherty JP. Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res. 1991;51:2041–2046
  38. Zimm S, Cleary SM, Lucas WE. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res. 1987;15:1712–1716
  39. McClay Ef, Goel R, Andrews P. A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. Br J Cancer. 1993;68:783–788
  40. Howell SB, Pfeifle CE, Olshen RA. Intraperitoneal chemotherapy with melphalan. Ann Intern Med. 1984;101:14–18
  41. Piccart MJ, Abrams J, Dodion PF. Intraperitoneal chemotherapy with cisplatin and melphalan. J Natl Cancer Inst. 1988;80:1118–1124
  42. Oza AM, Ten Bokkel Huinink W, Dubbelman R. Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. Ann Oncol. 1994;5:343–347
  43. Alberts DS, Surwit EA, Peng YM. Phase I clinical and pharmacological study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res. 1988;15:5874–5877
  44. Nicoletto MO, Padrini R, Ferrazzi E. Phase I-II intraperitoneal mitoxantrone in advanced pretreated patients. Eur J Cancer. 1993;29:1242–1248
  45. Blochl-Daum B, Eichler HG, Rainer H. Escalating dose regimen of intra peritoneal mitoxantrone: phase I study-clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol. 1988;24:1133–1138
  46. Husain A, Sabbatini P, Spriggs D. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Gynecol Oncol. 1999;73:96–101
  47. Kirmani S, McVey L, Loo D. A phase I clinical trial of intraperitoneal thiotepa for refractory ovarian cancer. Gynecol Oncol. 1990;36:331–334
  48. Wadler S, Egorin MJ, Zuhowski EG. Phase I pharmacokinetic study of hiotepa administered intraperitoneally in patients with advanced malignancies. J Clin Oncol. 1989;7:132–139
  49. Sugarbaker PH, Gianola FJ, Speyer JC. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:412–422
  50. Kuzuya T, Yamauchi M, Ito A. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin-C in intraperitoneal chemotherapy. J Pharm Pharmacol. 1994;46:685–689
  51. Speyer JL, Collins JM, Dedrick RL. Phase I and pharmacologic studies of 5-FU administered intraperitoneally. Cancer Res. 1980;40:567–572
  52. Howell SB, Chu BB, Wung HE. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest. 1981;67:1161–1170
  53. Jones RB, Collins JM, Myers CE. High volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res. 1981;41:55–59
  54. Ozols R, Young R, Speyer J. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265–4269
  55. Markman M, Howell SB, Lucas WE. Combination intraperitoneal chemotherapy with cisplatin, cytarabine and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol. 1984;2:1321–1326
  56. King M, Pfeifle C, Howell S. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol. 1984;2:662–669
  57. Piver S, Shasikant B, Marchetti D. Surgically documented response to intraperitoneal cisplatin, cytarabine and bleomycin after intravenous cisplatin based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol. 1988;11:1679–1684
  58. Markman M, Cleary S, Lucas WE. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol. 1985;3:925–931
  59. Bitran J. Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. Cancer. 1985;56:2420–2423
  60. Howell SB, Schieffer M, Andrews PA. The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol. 1987;5:2009–2016
  61. Markman M, Cleary S, Lucas W. IP chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin. Cancer Treat Rep. 1986;70:755–760
  62. Alberts DS, Liu PY, Hannigan EV. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  63. Kirmani S, Braly PS, McClay EF. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol. 1994;54:338–344
  64. Markman M, Bundy B, Benda J. Randomized phase III study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatinum followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer. Proc Am Soc Clin Oncol. 1998;17:#300
  65. Polyzos A, Tsavaris N, Kosmas C. A comparitive study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology. 1999;56:291–296
  66. Beller U, Speyer J, Colombo N. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer. J Clin Oncol. 1991;9:809–817
  67. Tarraza H, Boyce C, Smith W. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol. 1993;50:287–290
  68. Menczer J, Ben Baruch G, Rizel S. Intraperitoneal cisplatin in patients with ovarian carcinoma who are in clinically complete remission. Gynecol Oncol. 1992;46:222–225
  69. Barakat R, Almadrones L, Venkatraman E. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 1998;69:17–22
  70. Bruzzone M, Rubagotti A, Gadducci A. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look laparotomy: a prospective randomized trial of 111 patients. Gynecol Oncol. 1997;65:499–505
  71. Pujade-Lauraine E, Guastalla JP, Colombo N. Intraperitoneal interferon gamma in ovarian cancer patients with residual disease at second look. J Clin Oncol. 1996;14:343–350
  72. Dufour P, Bergerat JP, Barats JC. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer. 1994;73:1865–1869
  73. Howell S, Zimm S, Markman . Long-term survival of advanced refractory ovarian carcinoma patients treated with small volume disease treated with intra-peritoneal chemotherapy. J Clin Oncol. 1987;5:1607–1612
  74. Markman M, Reichman B, Hakes T. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol. 1992;10:1479–1484
  75. De Jong RS, Willemse PHB, Boonstra H. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second line treatment in patients with small volume residual disease. Eur J Cancer. 1995;31:709–713
  76. Reichman B, Markman M, Hakes T. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol. 1989;7:1327–1332
  77. Braly S. A phase II Gynecologic Oncology Group trial. Gynecol Oncol. 1995;56:164–168
  78. Piver S, Recio F, Baker T. Evaluation of survival after second-line intraperitoneal Cisplatin-based chemotherapy for advanced ovarian cancer. Cancer. 1994;73:1693–1698
  79. Markman M, Reichman B, Hakes T. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol. 1992;10:1479–1484
  80. Markman M, Reichman B, Hakes T. Responses to second line cisplatin based intraperitoneal chemotherapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9:1801–1805
  81. Recio F, Piver M, Hempling R. Five year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol. 1998;68:267–273
  82. Markman M, Brady M, Spirtos N. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: A Gynecologic Oncology Group Study. J Clin Oncol. 1998;16:2620–2624
  83. Markman M. Intraperitoneal therapy of ovarian cancer. Sem Oncol. 1998;25:356–360
  84. Orlando M, Huertas E, Salum G. Intraperitoneal hyperthermic chemotherapy as consolidation treatment for ovarian cancer in pathological complete remission. Proc Am Soc Clin Oncol. 1998;17:#1432
  85. Alvarez R, Partridge E, Khazaeli M. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94–101
  86. Freedman RS, Lenzi R, Kudelka AP. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther. 1998;4:121–140
  87. Steller MA, Egorin MJ, Trimble EL. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high dose carboplatin as primary treatment of patients with small volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43:106–114
  88. Berek JS, Hacker NF, Lichtenstein A. Intraperitoneal recombinant alpha-interferon for “salvage” immunotherapy in stage III epithelial ovarina cancer: a Gynecologic Oncology Group Study. Cancer Res. 1985;45:4447–4453
  89. Willemse PHB, De Vries EGE, Mulder NH. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer. 1990;26:353–358
  90. Friedlander M, Millward MJ, Bell D. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 1998;9:1343–1345
  91. Pestieau SR, Stuart OA, Chang D. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori. 1998;84:706–711
  92. Arts HJ, Willemse PHB, Tinga DJ. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma. Gynecol Oncol. 1998;69:32–35
  93. Nanninga AG, Willemse PHB, Boonstra H. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer. Int J Gynecol Oncol. 1992;2:107–110
  94. Von Grueningen VE, Santoso JT, Coleman RL. In vivo studies of adenovirus-based gene therapy for ovarian cancer. Gynecol Oncol. 1998;69:197–204
  95. Kim J, Hwang ES, Kim JS. Intraperitoneal gene therapy with adenoviral mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther. 1999;6:172–178
  96. Heise C, Sampson JA, Williams A. ONYX-015, an E1B gene attenuated adenovirus, causes tumor-specific cytolysis and antitumoral effects that can be augmented by standard chemotherapeutic agents. Nature Med. 1997;3:639–645
  97. Van der Zee AGJ, Hollema H, Suurmeijer AJ. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol. 1995;13:70–78

PII: S0305-7372(99)90152-4

doi: 10.1053/ctrv.1999.0152

Cancer Treatment Reviews
Volume 26, Issue 2 , Pages 133-143 , April 2000

Article Tools